Back to news

Delox: a unique technology for bio-decontamination and a new company in Hovione Capital’s portfolio.

22 . Jun . 2018
Share:
Linkedin
Hovione Capital announces an investment in Delox, a spin-off from the Faculty of Sciences of the University of Lisbon, which has developed an innovative, proprietary, solid hydrogen peroxide formulation technology enabling highly effective and affordable biodecontamination.

Worldwide, hospital-acquired infections still cause hundreds of thousands of deaths per year. Until now, Hospitals and other medical facilities have to make a choice regarding decontamination: either the system is effective or is a low-cost one. Could both these needs be met simultaneously?

Fortunately, Delox’s novel hydrogen-peroxide formulation, aims to achieve an affordable breakthrough that enables biocontamination to be routinely available everywhere. Additionally, Delox has a patented portable device that brings to the market an alternative to the large, expensive machines, that perform decontamination.

Hydrogen peroxide is a well-known sterilizer in the decontamination market, but what Delox is developing is a new approach to microbial sterilization that can be applied not only to medical spaces, but also to several other different situations.

What if biodefense and aerospace industries could be self-sufficient regarding their own sterilization needs? In 2017, Delox won 3 prizes and a 2nd place at Space Exploration Masters by the European Space Agency, Merck and Airbus.

The team is composed by two University Professors and two Researchers: Professor Fernando Antunes, a biochemical engineer and Professor João Pires da Silva, a chemical engineer; Fadhil Musa, a master in biochemistry, redox biology and biomaterials and Raquel Nogueira, a microbiology engineer.

Hovione Capital co-invested in this company with Caixa Capital, the venture capital arm of the Portuguese national bank Caixa Geral de Depósitos.
Your cookie settings

We ask you to accept cookies for the purpose of performance, social networking and advertising.
For more information or correct your preferences, press the button "more info".
For more information about these cookies and the processing of your personal data, check out our cookie and Privacy Policy. Accept these cookies and the processing of personal data involved?

Accept cookies More information